FDA opposition to legislation that would loosen conflict of interest rules does not seem to deter congressional efforts to include the requirement in the Prescription Drug User Fee Act reauthorization.
Battle Lines Clear On Conflict Of Interest Policy In PDUFA Reauthorization
Commissioner Hamburg says the agency likely does not need legislation to improve its conflict of interest policy, but House members still say the system needs reform. Industry and patient advocate groups push for change, while consumer groups press FDA to stand firm.
More from United States
Former Acting FDA Commissioner Sara Brenner is said to have asked Tracy Beth Høeg, new special assistant to the commissioner, to help reexamine the application. Høeg’s position at the agency is raising concerns about the FDA's ongoing approach to vaccine regulation.
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
As CMS administrator, Mehmet Oz will oversee the second year of Medicare drug price negotiations and Part D redesign issues, but will have experienced deputies to help.
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.
More from North America
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.